Enzo Biochem (Enzo Biochem) Gross Margin % : 49.39% (As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Enzo Biochem's Gross Profit for the three months ended in Jan. 2024 was $4.22 Mil. Enzo Biochem's Revenue for the three months ended in Jan. 2024 was $8.55 Mil. Therefore, Enzo Biochem's Gross Margin % for the quarter that ended in Jan. 2024 was 49.39%.

The historical rank and industry rank for Enzo Biochem's Gross Margin % or its related term are showing as below:

ENZ' s Gross Margin % Range Over the Past 10 Years
Min: 28.64 Med: 42.27 Max: 112.3
Current: 112.3

During the past 13 years, the highest Gross Margin % of Enzo Biochem was 112.30%. The lowest was 28.64%. And the median was 42.27%.

ENZ's Gross Margin % is ranked better than
99.07% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 45.595 vs ENZ: 112.30

Enzo Biochem had a gross margin of 49.39% for the quarter that ended in Jan. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Enzo Biochem was 3.10% per year.

Enzo Biochem Gross Margin % Historical Data

The historical data trend for Enzo Biochem's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Gross Margin % Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Gross Margin %

Get a 7-Day Free Trial

28.64

31.27

45.51

41.14

37.24

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Gross Margin %	Get a 7-Day Free Trial															38.57	10.17	-25.76	44.26	49.39

Competitive Comparison of Enzo Biochem's Gross Margin %

For the Diagnostics & Research subindustry, Enzo Biochem's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzo Biochem's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Gross Margin % falls into.

Enzo Biochem Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Enzo Biochem's Gross Margin for the fiscal year that ended in Jul. 2023 is calculated as

Gross Margin % (A: Jul. 2023 )	=	Gross Profit (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	11.6	/	31.061
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(31.061 - 19.495)	/	31.061
	=	37.24 %

Enzo Biochem's Gross Margin for the quarter that ended in Jan. 2024 is calculated as

Gross Margin % (Q: Jan. 2024 )	=	Gross Profit (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	4.2	/	8.553
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(8.553 - 4.329)	/	8.553
	=	49.39 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Enzo Biochem (NYSE:ENZ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Enzo Biochem had a gross margin of 49.39% for the quarter that ended in Jan. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Enzo Biochem Gross Margin % Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Gross Margin %

Comparable Companies

PRE DRIO PSNL AWH BIOQ MDXH OCX VNRX BIAF TTOO TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

EZB:Germany

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203